Not Signed In -
Immunization |
|
|
A child being immunized against Polio. For financial immunization, see Immunization (finance). Immunization, or immunisation, is the process by which an individual is exposed to an agent that is designed to fortify his or her immune system against that agent. The material is known as an immunogen. Immunization is the same as inoculation and vaccination in that inoculation and vaccination use a viable infecting agent like immunization does. Immunization is just the general term for va ...
Wikipedia - [full article]
Immunization Clinical Trials
- Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels
ClinicalTrials.gov Identifier: NCT00437671 - Recruiting
Tetanus
- Pneumococcal Adult-Dose Ranging Immunization Study
ClinicalTrials.gov Identifier: NCT00169234 - Active, not recruiting
Pneumonia
- A Phase 1, evaluation of Transgenic Lymphocyte Immunization vaccine in subjects with prostate adenocarcinoma.
ClinicalTrials.gov Identifier: NCT00061035 - Recruiting
Prostatic Neoplasms
- Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule
ClinicalTrials.gov Identifier: NCT00460486 - Active, not recruiting
Encephalitis, Tick-Borne
- Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease
ClinicalTrials.gov Identifier: NCT00174525 - Active, not recruiting
Alzheimer's Disease
- Pertussis Maternal Immunization Study
ClinicalTrials.gov Identifier: NCT00553228 - Recruiting
Pregnant Women
- Neonatal Immunization With Pneumococcal Conjugate Vaccine in Papua New Guinea
ClinicalTrials.gov Identifier: NCT00219401 - Recruiting
Pneumonia; Meningitis; Otitis Media
- Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides
ClinicalTrials.gov Identifier: NCT00365937 - Recruiting
Melanoma
- Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization
ClinicalTrials.gov Identifier: NCT00338377 - Recruiting
Melanoma
- Effect of Public Sector Antiretroviral Treatment Programme on Tuberculosis and Immunization Care
ClinicalTrials.gov Identifier: NCT00203762 - Recruiting
Tuberculosis
- Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors
ClinicalTrials.gov Identifier: NCT00353977 - Recruiting
Cytomegalovirus Infections
- Feasibility of Cocooning Immunization Strategy With Influenza Vaccine
ClinicalTrials.gov Identifier: NCT00570037 - Recruiting
Influenza
- Safety and Long-Term Evaluation (up to 5 Years) of First Booster Immunization With Novartis' TBE Vaccine for Adults in Adolescents and Adults
ClinicalTrials.gov Identifier: NCT00387634 - Recruiting
Tick Born Encephalitis
- Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma
ClinicalTrials.gov Identifier: NCT00116597 - Active, not recruiting
Melanoma
- Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity
ClinicalTrials.gov Identifier: NCT00393783 - Recruiting
Breast Cancer
- Primary Care and Adolescent Immunization for Rochester
ClinicalTrials.gov Identifier: NCT00581347 - Recruiting
Adolescent Immunizations; Preventive Care
- Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor
ClinicalTrials.gov Identifier: NCT00377247 - Recruiting
Primary Advanced Carcinoma of the Oral Cavity or Oropharynx; Squamous Cell Carcinoma of the Head and Neck
- Immunization with 8 Peptides Mixed with Adjuvant CpG 7909 in HLA-A2 Patients with Metastatic Cutaneous Melanoma
ClinicalTrials.gov Identifier: NCT00145158 - Recruiting
Malignant Melanoma
- Immunization Against Tumor Cells in Sezary Syndrome
ClinicalTrials.gov Identifier: NCT00099593 - Recruiting
Cutaneous T-Cell Lymphoma; Sezary Syndrome
- Trial to Reduce Alloimmunization to Platelets (TRAP)
ClinicalTrials.gov Identifier: NCT00000589 - Completed
Blood Platelets; Hematologic Diseases; Immunization; Leukemia, Myelocytic, Acute; Blood Transfusion
- Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma
ClinicalTrials.gov Identifier: NCT00072085 - Completed
Melanoma (Skin)
- Studies of In Vitro B Lymphocyte Responses in Subjects Receiving Tetanus Toxoid Booster Immunization
ClinicalTrials.gov Identifier: NCT00001173 - Completed
Healthy
- Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)
ClinicalTrials.gov Identifier: NCT00163540 - Completed
Encephalitis, Tick-Borne
- Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer
ClinicalTrials.gov Identifier: NCT00292045 - Completed
Prostate Cancer
- Immunization of Patients with Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence
ClinicalTrials.gov Identifier: NCT00001705 - Completed
Melanoma; Neoplasm Metastasis
- Immunization of HLA-A201 Patients with Metastatic Melanoma Using a Combination of Immunodominant Peptides from Three Melanoma Antigens, MART-1, GP100 and Tyrosinase
ClinicalTrials.gov Identifier: NCT00001685 - Completed
Melanoma; Neoplasm Metastasis
- Immunization of Patients with Metastatic Melanoma Using Recombinant Fowlpox Virus Encoding a gp100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence
ClinicalTrials.gov Identifier: NCT00001800 - Completed
Melanoma; Neoplasm Metastasis
- Immunogenicity and Safety Study of a Rapid Immunization Schedule with FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years
ClinicalTrials.gov Identifier: NCT00161954 - Completed
Encephalitis, Tick-Borne
- Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity
ClinicalTrials.gov Identifier: NCT00000977 - Completed
HIV Infections
- Immunization of Patients with Metastatic Melanoma Using MART-1 and GP100 Peptides Modified to Increase Binding to HLA-0201
ClinicalTrials.gov Identifier: NCT00001808 - Completed
Melanoma; Neoplasm Metastasis
- Immunization of Patients with Metastatic Melanoma Using DNA Encoding the GP100 Melanoma Antigen
ClinicalTrials.gov Identifier: NCT00001692 - Completed
Melanoma; Neoplasm Metastasis
- Phase I Trial in Patients with Metastatic Melanoma of Immunization with a Recombinant Fowlpox Virus Encoding the gp100 Melanoma Antigen
ClinicalTrials.gov Identifier: NCT00001510 - Completed
Melanoma; Neoplasm Metastasis
- Phase I Study in Patients with Metastatic Melanoma of Immunization with Dendritic Cells Presenting Epitopes Derived from the Melanoma Associated Antigen MART-1 and gp100
ClinicalTrials.gov Identifier: NCT00001558 - Completed
Melanoma; Neoplasm Metastasis
- Immunization of Patients with Metastatic Melanoma Using Recombinant Fowlpox and Vaccinia Viruses Encoding the Tyrosinase Antigen
ClinicalTrials.gov Identifier: NCT00001811 - Completed
Melanoma; Neoplasm Metastasis
- Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)
ClinicalTrials.gov Identifier: NCT00001041 - Completed
HIV Infections; Pregnancy
- Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation
ClinicalTrials.gov Identifier: NCT00001561 - Completed
Graft vs Host Disease; Multiple Myeloma
- Immunization of Patients with Metastatic Melanoma Using Immunodominant Peptides from the Tyrosinase Protein, Tyrosinase Related Protein-1 (TRP1), or GP100 Protein
ClinicalTrials.gov Identifier: NCT00001684 - Completed
Melanoma; Neoplasm Metastasis
- Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)
ClinicalTrials.gov Identifier: NCT00000777 - Completed
HIV Infections; Pregnancy; HIV Seronegativity
- Rituximab in the Treatment of Graves´ Disease.
ClinicalTrials.gov Identifier: NCT00150111 - Completed
Graves´ disease; Thyroid Associated Ophthalmopathy
- Peptide-Sensitized Lymphocytes plus melanoma peptide immunization followed by IL-2 to Treat Patients with Melanoma
ClinicalTrials.gov Identifier: NCT00076661 - Completed
Melanoma; Neoplasm Metastasis
- A Phase III Multi-Institutional Randomized Study of Immunization with the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients with Metastatic Melanoma
ClinicalTrials.gov Identifier: NCT00001801 - Completed
Melanoma; Neoplasm Metastasis
- Vaccine Therapy in Treating Patients With Progressive Prostate Cancer
ClinicalTrials.gov Identifier: NCT00066261 - Suspended
adenocarcinoma of the prostate; recurrent prostate cancer; stage IV prostate cancer
- A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 cells/mm3
ClinicalTrials.gov Identifier: NCT00001064 - Terminated
HIV Infections
- Effects of Immunization with HIV-1 Immunogen Plus Anti-HIV Treatment Interruption on the Levels of HIV
ClinicalTrials.gov Identifier: NCT00021762 - Terminated
HIV Infections
- Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)
ClinicalTrials.gov Identifier: NCT00001046 - Terminated
HIV Infections; Pregnancy; HIV Seronegativity
- Immunization with the MAGE-3.A1 Peptide Mixed with the Adjuvant CpG 7909 in Patients with Metastatic Melanoma
ClinicalTrials.gov Identifier: NCT00145145 - Terminated
Malignant Melanoma
Resources
- (National Women's Health Information Center, OWH, HHS)
- 10 Important Vaccine Facts for Seniors (Centers for Disease Control and Prevention) - Links to PDF File
email this page
print this page
bookmark this page
feedback on this page
